| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442725 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
GI is validated here as a robust marker to predict intermediate-GIST clinical outcome. Applicable in numerous Pathology Laboratories already using array comparative genomic hybridisation (CGH) with formalin-fixed paraffin-embedded (FFPE) samples, this assay presently stands as an efficient tool for the clinical management of intermediate GIST-patients.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Lydia Lartigue, Agnès Neuville, Pauline Lagarde, Céline Brulard, Piotr Rutkowski, Paolo Dei Tos, Eva Wardelmann, Maria Debiec-Rychter, Antoine Italiano, Jean-Michel Coindre, Frédéric Chibon,